Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration

Xu,Jia-Ying; Meng,Qing-Hui; Chong,Yu; Jiao,Yang; Zhao,Lin; Rosen,Eliot  M.; Fan,Saijun

doi:10.3892/mco.2012.41

Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration

Authors:
- Jia-Ying Xu
- Qing-Hui Meng
- Yu Chong
- Yang Jiao
- Lin Zhao
- Eliot M. Rosen
- Saijun Fan
View Affiliations

Affiliations: School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
Published online on: November 20, 2012 https://doi.org/10.3892/mco.2012.41
Pages: 331-336

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is a main angiogenic factor which is known to be upregulated in lung cancer. In the present study, it was demonstrated that sanguinarine, an alkaloid obtained from the bloodroot plant, markedly repressed the VEGF-induced tube formation of human microvascular endothelial cells (HMVECs) and the migration of human A549 lung cancer cells. Furthermore, sanguinarine decreased VEGF secretion and expression in HMVECs and A549 lung cancer cells in a dose- and time-dependent manner. Additionally, sanguinarine inhibited the activation of serum starvation- and hypoxia-induced VEGF promoter activity. Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation. To the best of our knowledge, this is the first study demonstrating that VEGF inhibition appears to be an important mechanism involved in the antiangiogenic and anti-invasive activities of sanguinarine in lung cancer treatment.

View Figures

View References

1	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ebos JM and Kerbel RS: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
3	Farhat FS, Tfayli A, Fakhruddin N, et al: Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. Apr 9–2012.(Epub ahead of print).
4	Das M and Wakelee H: Targeting VEGF in lung cancer. Expert Opin Ther Targets. 16:395–406. 2012. View Article : Google Scholar
5	Aggarwal C, Somaiah N and Simon G: Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 13:247–263. 2012. View Article : Google Scholar : PubMed/NCBI
6	Blakely C and Jahan T: Emerging antiangiogenic therapies for non-small cell lung cancer. Expert Rev Anticancer Ther. 11:1607–1618. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lind JS and Smit EF: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol. 1:95–107. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mackraj I, Govender T and Gathiram P: Sanguinarine. Cardiovasc Ther. 26:75–83. 2008.
9	Sun M, Liu C, Nadiminty N, Lou W, et al: Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 72:82–89. 2012. View Article : Google Scholar : PubMed/NCBI
10	De Stefano I, Raspaglio G and Zannoni GF: Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. Biochem Pharmacol. 78:1374–1381. 2009.PubMed/NCBI
11	Tsukamoto H, Kondo S, Mukudai Y, et al: Evaluation of anticancer activities of benzo[c]phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line. Anticancer Res. 31:2841–2946. 2011.
12	Jang BC, Park JG and Song DK: Sanguinarine induces apoptosis in A549 human lung cancer cells primarily via cellular glutathione depletion. Toxicol In Vitro. 23:281–287. 2009. View Article : Google Scholar : PubMed/NCBI
13	Eun JP and Koh GY: Suppression of angiogenesis by the plant alkaloid, sanguinarine. Biochem Biophys Res Commun. 317:618–624. 2004. View Article : Google Scholar : PubMed/NCBI
14	Basini G, Bussolati S, Santini SE and Grasselli F: Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix. Biofactors. 29:11–18. 2007. View Article : Google Scholar : PubMed/NCBI
15	Basini G, Santini SE, Bussolati S and Grasselli F: Sanguinarine inhibits VEGF-induced Akt phosphorylation. Ann N Y Acad Sci. 1095:371–376. 2007. View Article : Google Scholar : PubMed/NCBI
16	Basini G, Santini SE, Bussolati S and Grasselli F: The plant alkaloid sanguinarine is a potential inhibitor of follicular angiogenesis. J Reprod Dev. 53:573–579. 2007. View Article : Google Scholar : PubMed/NCBI
17	Pica F, Balestrieri E, Serafino A, et al: Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. Anticancer Drugs. 23:32–42. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fan S, Ma YX and Wang C: p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 62:141–151. 2002.PubMed/NCBI
19	Choi YH, Choi WY, Hong SH, et al: Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 179:185–191. 2009. View Article : Google Scholar
20	Chang MC, Chan CP, Wang YJ, et al: Induction of necrosis and apoptosis to KB cancer cells by sanguinarine is associated with reactive oxygen species production and mitochondrial membrane depolarization. Toxicol Appl Pharmacol. 218:143–151. 2007. View Article : Google Scholar